查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856204

DNA定序市场：按产品供应、工作流程、技术类型、应用和最终用户划分－2025-2032年全球预测

DNA Sequencing Market by Offerings, Workflow, Technology Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，DNA 定序市场规模将达到 329.5 亿美元，复合年增长率为 11.90%。

关键市场统计数据
基准年 2024 133.9亿美元
预计年份：2025年 149.2亿美元
预测年份 2032 329.5亿美元
复合年增长率 (%) 11.90%

全面介绍定定序技术进步、监管压力以及产业相关人员之间的资料工作流程整合的整合背景

引言部分将本执行摘要定位为对DNA定序技术最新发展及其对科研、临床诊断和产业相关人员的策略影响的关键性综合分析。它阐述了技术创新、法规环境、供应链韧性和商业策略之间不断演变的相互作用，重点强调了化学和仪器技术的渐进式改进如何带来广泛的应用和操作复杂性。概述部分阐明了为何需要采用综合观点。科技的快速普及、跨行业的应用以及对数据管理日益增长的需求，正在形成一个战术性和战略选择决定竞争优势的格局。

本文以基础概念为基础，概述了塑造该领域的关键因素，涵盖模组化硬体设计、试剂专业化、软体和分析整合等。文章强调了定序平台与下游生物资讯学的融合，指出从样本处理到比对、註释和变异检测的无缝工作流程已成为获得可靠结果的先决条件。此外，文章还着重介绍了服务模式的日益普及，例如合约定序和客製化panel设计，这些模式使用户无需投入大量资金来建立内部平台即可获得所需的功能。

最后，引言为摘要的其余部分定下了基调，将技术成熟度与采购、监管合规和人才获取等方面的实际问题联繫起来，并强调了采取整体方法的重要性，该方法平衡了眼前的业务重点与对能力、伙伴关係和数据管治的长期投资，以维持科学和商业性目标。

识别正在迅速重塑定序营运模式和竞争格局的技术服务和监管曲折点

DNA定序领域正再形成一系列变革性转变，这些转变正共同改变研究机构、临床实验室和商业性营业单位的运作方式。定序化学和平台工程的进步提高了定序通量和读取准确性，同时减少了每个样本的人工操作时间，从而催生了新的研究设计和诊断流程。同时，第三代定序平台的成熟拓展了长读长定序的应用范围，使结构变异检测和复杂基因组组装变得更加便利。这些技术进步，以及对优化端到端工作流程（包括样本製备、文库建构和整合分析）的日益重视，旨在最大限度地减少变异性并加快结果的获取速度。

同时，经营模式创新正在加速发展。服务供应商正在扩大其合约定定序，并提供模组化分析包，从而能够外包客製化面板设计和复杂资料解读等专业任务。这种服务和耗材专业化的趋势，与仪器设计领域向可扩展、可互通平台发展的平行趋势相呼应，这些平台可根据通量需求进行客製化。法律规范和支付方的考量也在不断演变，要求临床应用必须展现可靠的验证、可重复性和明确的临床效用。因此，业内相关人员正在投资于品质系统、标准化通讯协定以及旨在简化认证流程的伙伴关係。

最后，数据管理和运算能力已成为竞争力的关键。为了从日益增长的资料量中提取可操作的洞见，必须改进比对、组装、註释和变异检测演算法。投资于安全、可扩展的数据基础设施，并配备技术精湛的生物资讯团队，如今已成为那些致力于将测序结果转化为转化研究、定序决策支援和商业性研发成果的机构的战略重点。

评估2025年贸易措施如何重塑了定序业务的采购架构、供应弹性和供应商伙伴关係。

2025年关税和贸易措施的实施为定序系统带来了新的营运考量，影响了筹资策略、供应商关係和成本管理实务。进口关税的变化影响了资本设备和某些试剂的来源，促使采购负责人分散供应商组合，并重新考虑长期服务合同，以降低政策波动带来的风险。为此，许多机构优先选择本地经销商和区域製造商，以缩短跨境物流的前置作业时间和降低不确定性，同时维持优惠的服务水准安排，确保营运的连续性。

此外，关税促使买家更加谨慎地进行库存计划和合约结构设计，以平衡营运成本限制和安全库存。合约谈判中越来越多地纳入了有关关税转嫁、外汇波动和应急供应安排的条款。对于实验室和服务提供者而言，这导致他们更加重视营运效率，包括流程自动化和试剂节约策略，以抵消进口耗材和设备到岸成本上涨的影响。

关税环境也加速了国内生产和试剂本地化配製的讨论，以减少对单一供应商的依赖。仪器供应商、耗材製造商和本地委託製造製造商正在考虑建立策略联盟，以建立更具韧性的供应链。整体而言，2025年关税环境的累积影响正促使相关人员采用更灵活的采购框架，投资于供应链情报，并寻求结构性调整，以在不断变化的贸易环境中维持研究的连续性和诊断的可靠性。

明确工作流程技术应用与最终用户需求的交汇点，以创造差异化价值并确定投资机会的优先顺序。

关键的细分洞见揭示了在整个定序价值定序中，哪些环节的投资、能力发展和策略差异化最为关键。基于产品和服务，市场可细分为耗材和试剂、仪器和平台以及服务。耗材和试剂尤其值得关注的是其技术上的细分，分为酵素和缓衝液以及引子和探针。仪器和平台涵盖了从DNA定序仪到文库建构系统和PCR仪等多种类型，工作流程的互通性会影响其应用。服务不仅限于基础定定序，还包括合约定定序、客製化panel设计以及数据分析和解读，为透过长期合约和专业知识实现价值获取提供了途径。

从工作流程的角度来看，流程分割凸显了贯穿资料分析、文库建构、样本製备和定序本身的端到端流程一致性的重要性。数据分析分为关键功能组件，包括比对和组装、註释和变异检测，每个组件都需要有效的演算法和特定领域的专业知识。样本製备包括DNA萃取和品管，这些步骤直接影响下游读取品质和结果的可靠性。有效编配这些工作流程步骤可以降低变异性，并提高对研究结果和临床决策的信心。

次世代定序(NGS) 在高通量应用中占据主导地位，Sanger 定序仍然是标靶验证和毛细管检测的标准方法，而第三代定序(TGS) 则为解析复杂的基因组特征提供了长读长应用。应用领域涵盖农业基因组学、药物研发、遗传疾病研究、微生物学（包括微生物组分析和病原体检测）、肿瘤学（包括癌症基因分型和肿瘤谱分析）、个人化医疗和产前检测。每种应用都有其独特的技术、监管和分析要求，从而影响采购和伙伴关係的选择。最终用户包括学术和研究机构（例如政府研究机构和大学实验室）、受託研究机构、医院、诊断实验室以及製药和生物技术公司。每个最终用户都有其自身的处理能力、品质标准和服务偏好，这些都会影响供应商的打入市场策略。

影响全球各地区策略市场策略的监管环境，以及影响各地区供应链优先事项的采用驱动因素

来自各个地区的洞察揭示了企业在定位其定序资产和规划市场进入方式上的不同策略重点和营运环境。在美洲，强大的研究资助体系和成熟的临床基因组学计画支撑了对先进平台、全面的试剂组合和整合检测的高需求。这种环境有利于那些能够提供检验的临床工作流程、强大的售后支援以及加速转化研究的合作研究伙伴关係的供应商和服务供应商。虽然跨境供应链仍然重要，但扩大关键耗材的国内生产能力以增强韧性也备受关注。

在欧洲、中东和非洲，统一的监管环境和分散的报销体系促使企业采取谨慎而审慎的实施路径，优先考虑临床效用和符合当地认证要求。能够提供完善的品管系统、在地化支援和在地化验证方案的供应商正赢得客户的青睐。同时，在亚太地区，我们看到能力和规模的多样性：成熟市场正在快速采用高通量NGS和新兴的长读长定序技术，而发展中市场则优先考虑可扩展、经济高效的平台和耗材，以支持公共卫生和农业基因组学计画。在所有地区，本地伙伴关係、人才培养和植根于当地的服务倡议对于持续合作和商业性成功至关重要。

分析策略伙伴关係和专业服务模式如何影响定序的竞争差异化和下游应用。

本报告重点阐述了主要企业和新兴企业如何围绕核心竞争力、伙伴关係模式和服务组合进行市场定位，从而在整个定序生态系统中获取价值。一些公司正大力投资于平台性能和化学创新，以确保技术差异化；而另一些公司则在拓展耗材产品组合和服务能力，以创造持续的收入来源。仪器製造商和试剂供应商之间的策略联盟日益普遍，使他们能够提供捆绑式产品，从而简化采购流程并加快终端用户的检验速度。同时，越来越多的服务供应商和专业分析公司正透过先进的生物资讯学、法规支援以及面向临床的复杂应用场景工作流程来实现差异化竞争优势。

併购和授权协议仍是弥补能力缺口、开拓新区域市场以及整合专有检测方法和计算流程的重要手段。需要快速部署、认证支援和全生命週期维护的临床和诊断实验室更青睐拥有强大销售管道和本地化技术支援的行业参与者。新参与企业通常在长读长结构变异分析和高通量多重检测等细分应用领域竞争，并强调与临床和研究机构建立合作关係以检验应用案例。在整个竞争格局中，产品开发的敏捷性、强大的售后支援以及清晰的监管和品质文件正成为影响采购决策和长期客户关係的关键差异化因素。

为技术开发人员、服务供应商和负责人提供切实可行的策略指导，以使其产品模组化、监管合规性和供应链弹性与成长目标保持一致。

针对产业领导者的实际建议着重于协调技术开发、商业策略和营运韧性，以实现永续优势。领导者应优先考虑模组化平台设计和开放式仪器生态系统，以促进第三方耗材的集成，并降低客户的整体拥有成本。投资于试剂可靠性和​​标准化文库製备试剂套件，并辅以清晰的验证方案，将减少临床和高通量研究使用者实施过程中的阻力。同时，将涵盖比对、组装、註释和变异检测等强大的分析功能整合到产品套件和服务中，将增强产品的感知价值提案，并使客户能够更快地获得可操作的洞察。

在供应和采购方面，企业必须实现采购管道多元化，并考虑建立区域製造伙伴关係，以降低贸易和关税风险。透过合约排序、客製化样本设计和资料解读管理服务，建立以服务为中心的收入来源，可以平稳收入波动并加深客户关係。积极主动地为客户提供验证包、合规文件和上市后监测证​​据，可以加速临床应用并减少报销障碍。最后，结合培训计画、技术支援和合作研究倡议的人才策略，可以帮助企业在不降低品质的前提下，维持高标准的服务并扩大营运规模。

透明的多来源调查方法，结合相关人员访谈、文献综述和工作流程分析，检验了业界考察和结论。

本执行摘要的调查方法融合了多种定性和定量方法，以确保研究结果的稳健性和可重复性。主要研究包括对行业高管、实验室主任和采购专业人员进行结构化访谈，以获取关于技术采纳、检验要求和供应链动态的第一手观点。次要研究整合了同行评审文献、监管指导文件、技术白皮书和公司披露信息，以检验更广泛的科学和商业性环境中的趋势，并整理访谈内容。透过对这些资讯来源进行三角验证，最大限度地减少偏差，并为主题结论提供支持。

此分析架构着重于价值链分解、工作流程映射和能力差距分析，以识别摩擦和机会并存之处。細項分析旨在反映真实的采购和业务行为，将产品、工作流程、技术类型、应用和最终用户与部署和规模化的实际考虑相匹配。品管包括使用独立实验室报告交叉检验技术声明，并透过与多家经销商访谈来确认供应链声明。调查方法强调假设的透明度、可复现的文献综述搜寻策略以及清晰的访谈通讯协定，以便为未来的更新和客製化研究扩展提供支持。

本文简要总结了技术法规和商业性趋势对建构韧性能力和竞争优势定位的影响，并确定了优先事项。

结论综合分析了技术进步、监管演变、地理差异以及商业策略等核心因素对定序领域相关人员的影响。化学和平台设计的技术改进拓展了可行应用范围，而服务和耗材的专业化则提供了灵活的实施路径，无需大量资本投资。监管和贸易的变化凸显了营运适应性的必要性，尤其是在采购和供应链规划方面，以及与认证和报销相关人员的积极互动。综上所述，这些动态有利于那些能够将可靠的仪器、检验的耗材、整合的分析系统和响应迅速的支援网络相结合的机构。

未来的成功取决于如何在确保供应链韧性和分析结果可重复性等紧迫业务需求与持续投资于平台差异化和员工能力建设之间取得平衡。积极寻求策略伙伴关係、在必要时实现关键供应能力的在地化，并提供清晰的检验方案的机构，更有可能降低临床和研究领域的应用门槛。同样重要的是，投资于安全、可扩展的数据基础设施和先进的生物资讯技术，将原始定序结果转化为具有临床意义且科学严谨的洞见。这种整合式方法将使相关人员能够在应对快速变化的技术和法规环境所带来的复杂性的同时，掌握不断涌现的机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 引入即时奈米孔定序，用于携带式现场诊断和流行病学研究
  • 单细胞多组体学整合技术的进步使得高解析度细胞分析成为可能。
  • ctDNA液态切片检测在癌症早期检测和监测的临床应用
  • 开发长读长定序平台以提高复杂基因组中结构变异的检测能力
  • 扩展基于 CRISPR 的定序方法以进行标靶序列捕获和甲基化分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. DNA定序市场依产品/服务分类

  • 耗材和试剂
    • 酵素和缓衝液
    • 引子和探针
  • 设备与平台
    • DNA定序仪
    • 图书馆製备系统
    • PCR装置
  • 服务
    • 定序合约
    • 客製化面板设计
    • 数据分析与解读

9. 按工作流程分類的DNA定序市场

  • 数据分析
    • 校准与装配
    • 註解
    • 变异调用
  • 图书馆准备
  • 样品製备
    • DNA萃取
    • 品管
  • 顺序

第十章：依技术类型分類的DNA定序市场

  • 下一代定序（NGS）
  • 桑格定序
  • 第三代定序（TGS）

第十一章 DNA定序市场依应用领域划分

  • 农业基因组学
  • 药物发现
  • 遗传疾病研究
  • 微生物学
    • 微生物组分析
    • 病原体检测
  • 肿瘤学
    • 癌症基因基因型鉴定
    • 肿瘤谱分析
  • 个人化医疗
  • 产前检查

第十二章 DNA定序市场（依最终用户划分）

  • 学术和研究机构
    • 政府研究所
    • 大学研究机构
  • 受託研究机构
  • 医院和诊断实验室
  • 製药和生物技术公司

13. 按地区分類的DNA定序市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 DNA定序市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国DNA定序市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • BGI Genomics Co., Ltd.
    • Bio-Rad Laboratories, Inc.
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd.
    • Laboratory Corporation of America Holdings
    • Azenta, Inc.
    • Illumina, Inc.
    • Macrogen Inc.
    • Oxford Nanopore Technologies PLC
    • PerkinElmer, Inc.
    • QIAGEN NV
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific Inc.
    • Twist Bioscience Corporation
    • Abbott Laboratories
    • Danaher Corporation
    • Merck KGaA
    • Pacific Biosciences of California, Inc.
    • Novogene Co, Ltd.
    • Shimadzu Corporation
    • Genomics England
    • Eppendorf SE
    • 10x Genomics, Inc.
    • BioChain Institute Inc.
    • Genscript Biotech Corporation
    • Sartorius AG
    • Charles River Laboratories International, Inc.
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Partek Inc.
    • Novartis AG
Product Code: MRR-450A0628CCF5

The DNA Sequencing Market is projected to grow by USD 32.95 billion at a CAGR of 11.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.39 billion
Estimated Year [2025] USD 14.92 billion
Forecast Year [2032] USD 32.95 billion
CAGR (%) 11.90%

Comprehensive opening context framing the convergence of sequencing technology advances regulatory pressures and data workflow integration across industry stakeholders

The introduction positions this executive summary as an essential synthesis of contemporary developments in DNA sequencing technologies and their strategic implications for stakeholders across research, clinical diagnostics, and industry. It frames the evolving interplay between technical innovation, regulatory environments, supply chain resiliency, and commercial strategy, emphasizing how incremental improvements in chemistry and instrumentation are translating into broader application scope and operational complexity. This overview clarifies why a consolidated perspective is necessary: rapid technology diffusion, cross-sector adoption, and heightened data management demands create a landscape where tactical and strategic choices determine competitive advantage.

Building on foundational concepts, the introduction outlines the principal vectors shaping the sector, from modular hardware design and reagent specialization to software and analytics integration. It highlights the convergence between sequencing platforms and downstream bioinformatics, where seamless workflows from sample handling through alignment, annotation, and variant calling are becoming a prerequisite for reliable outputs. The narrative also signals growing emphasis on service models, including contract sequencing and custom panel design, which allow organizations to access capabilities without the full capital outlay associated with in-house platforms.

Finally, the introduction establishes the tone for the remainder of the summary by linking technological maturation with pragmatic concerns for procurement, regulatory adherence, and talent acquisition. It underscores the importance of adopting a holistic approach that balances immediate operational priorities with longer-term investments in capabilities, partnerships, and data governance that will sustain scientific and commercial objectives.

Identifying the technological service and regulatory inflection points that are rapidly redefining operational models and competitive dynamics in sequencing

The landscape of DNA sequencing is being reshaped by a set of transformative shifts that collectively alter how research institutions, clinical laboratories, and commercial entities operate. Advances in sequencing chemistry and platform engineering are increasing throughput and read accuracy while reducing per-sample hands-on time, which in turn enables new study designs and diagnostic workflows. At the same time, the maturation of third-generation platforms has expanded capability envelopes for long-read applications, making structural variant detection and complex genome assembly more accessible. These technological gains are complemented by greater emphasis on end-to-end workflow optimization, where sample preparation, library construction, and integrated analytics are designed to minimize variability and accelerate time to result.

Concurrently, business model innovation is accelerating. Service providers are scaling contract sequencing and offering modular analytics packages that allow clients to outsource specialized tasks such as custom panel design or complex data interpretation. This shift toward services and consumable specialization is supported by a parallel trend in instrument design toward scalable, interoperable platforms that can be tailored to throughput needs. Regulatory frameworks and payer considerations are also evolving, pushing clinical applications to demonstrate robust validation, reproducibility, and clear clinical utility. As a result, industry players are investing in quality systems, standardized protocols, and partnerships that streamline certification pathways.

Finally, data stewardship and computational capacity have become central to competitiveness. Enhanced algorithms for alignment, assembly, annotation, and variant calling are necessary to extract actionable insights from growing data volumes. Investment in secure, scalable data infrastructure, combined with skilled bioinformatics teams, is now a strategic priority for organizations aiming to translate sequencing outputs into translational research, diagnostic decision support, or commercial R&D outcomes.

Assessing how 2025 trade measures have reshaped procurement architectures supply resilience and supplier partnerships across sequencing operations

The introduction of tariffs and trade measures in 2025 has introduced new operational considerations throughout the sequencing ecosystem, affecting procurement strategies, supplier relationships, and cost management practices. Changes to import duties have influenced where capital equipment and certain reagents are sourced, prompting procurement leads to diversify supplier portfolios and to reexamine long-term service agreements to mitigate exposure to policy volatility. In response, many organizations have prioritized local distributors and regional manufacturers to reduce lead times and uncertainty associated with cross-border logistics, while maintaining preferential service-level arrangements to preserve continuity of operations.

Moreover, tariffs have led to more deliberate inventory planning and contract structuring, as purchasers balance safety stock against working capital constraints. Contract negotiations increasingly include clauses that address tariff pass-through, currency fluctuations, and contingency supply arrangements. For laboratories and service providers, the consequence has been a renewed focus on operational efficiency, including process automation and reagent conservation strategies, to offset the impact of higher landed costs for certain imported consumables and instruments.

The tariff environment has also accelerated discussions around in-country manufacturing and localized reagent formulation to reduce dependence on single points of supply. Strategic partnerships between instrument vendors, consumable manufacturers, and local contract manufacturers are being explored to create more resilient supply networks. Overall, the cumulative impact of the 2025 tariff landscape is prompting stakeholders to adopt more flexible procurement frameworks, invest in supply chain intelligence, and pursue structural adjustments that preserve research continuity and diagnostic reliability in a shifting trade environment.

Uncovering where offerings workflow technology applications and end-user needs converge to create differentiated value and targeted investment priorities

Key segmentation insights illuminate where investment, capability development, and strategic differentiation are most consequential across the sequencing value chain. Based on product and service offerings, the market differentiates between consumables and reagents, instruments and platforms, and services. Consumables and reagents merits particular attention with its technical bifurcation into enzymes and buffers versus primers and probes, both of which drive assay performance and reproducibility. Instruments and platforms span DNA sequencers, library preparation systems, and PCR machines, and their interoperability with workflows influences adoption. Services extend beyond basic sequencing to encompass contract sequencing, custom panel design, and data analysis and interpretation, offering routes to capture value through recurring engagements and specialized expertise.

When examined through the workflow lens, segmentation highlights the importance of end-to-end process coherence across data analysis, library preparation, sample preparation, and sequencing itself. Data analysis divides into critical functional components such as alignment and assembly, annotation, and variant calling, each requiring validated algorithms and domain-specific expertise. Sample preparation includes DNA extraction and quality control, stages that directly affect downstream read quality and result reliability. Effective orchestration across these workflow stages reduces variability and enhances confidence in both research outcomes and clinical decisions.

Technology type remains a principal axis of differentiation, with Next-Generation Sequencing (NGS) dominating high-throughput applications, Sanger sequencing remaining a staple for targeted validation and capillary-based assays, and Third-Generation Sequencing (TGS) enabling long-read applications that resolve complex genomic features. Application segmentation spans agricultural genomics, drug discovery, genetic disease research, microbiology-which itself includes microbiome analysis and pathogen detection-oncology with cancer genotyping and tumor profiling, personalized medicine, and prenatal testing. Each application imposes distinct technical, regulatory, and analytical requirements, shaping procurement and partnership choices. Finally, end users range from academic and research institutions, which include government research institutes and university labs, to contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies; each end-user category has unique throughput expectations, quality standards, and service preferences, informing vendor go-to-market strategies.

Differentiating regional adoption drivers regulatory conditions and supply chain priorities that determine strategic market approaches across global geographies

Regional insights reveal divergent strategic priorities and operational conditions that inform how organizations deploy sequencing assets and plan market entry. In the Americas, strong research funding ecosystems and established clinical genomics programs support high demand for advanced platforms, comprehensive reagent portfolios, and integrated analytics. This environment favors vendors and service providers that can deliver validated clinical workflows, strong post-sale support, and collaborative research partnerships that accelerate translational pipelines. Cross-border supply chains remain important, but there is also a pronounced interest in capacity expansion for domestic production of critical consumables to strengthen resilience.

Across Europe, the Middle East & Africa, regulatory harmonization and fragmented reimbursement landscapes drive a cautious but methodical adoption path, where demonstrable clinical utility and compliance with regional certification are paramount. Vendors that offer robust quality management systems, localized support, and regionally adapted validation packages find receptive customers. In contrast, the Asia-Pacific region exhibits heterogeneity in capability and scale, with mature markets rapidly deploying both high-throughput NGS and emerging long-read technologies, while developing markets prioritize scalable, cost-efficient platforms and consumables that can support public health and agricultural genomics initiatives. Across all regions, regional partnerships, talent development, and localized service models are central to sustained engagement and commercial success.

Analyzing how corporate strategies partnerships and specialized service models are shaping competitive differentiation and downstream adoption in sequencing

Key company insights focus on how leading and emerging players are positioning around core competencies, partnership models, and service portfolios to capture value across the sequencing ecosystem. Some organizations are concentrating investment on platform performance and chemistry innovation to secure technological differentiation, while others are expanding their consumable portfolios and service capabilities to generate recurring revenue streams. Strategic alliances between instrument manufacturers and reagent suppliers are becoming more common, enabling bundled offerings that simplify procurement and shorten validation timelines for end users. Simultaneously, a cohort of service providers and specialized analytics companies are distinguishing themselves through advanced bioinformatics, regulatory support, and clinically oriented workflows that address high-complexity use cases.

Mergers, acquisitions, and licensing agreements remain instrumental tools for filling capability gaps, accessing new regional markets, and integrating proprietary assays or computational pipelines. Industrial players with robust distribution channels and localized technical support are favored by clinical and diagnostic laboratories that require rapid installation, certification support, and lifecycle maintenance. New entrants often compete on niche applications, such as long-read structural variant analysis or highly multiplexed panel assays, leveraging focused clinical or research partnerships to validate use cases. Across the competitive landscape, agility in product development, depth of post-market support, and clarity of regulatory and quality documentation are recurring differentiators that influence procurement decisions and long-term customer relationships.

Practical strategic guidance for technology developers service providers and purchasers to align product modularity regulatory preparedness and supply resilience with growth objectives

Actionable recommendations for industry leaders emphasize aligning technology development, commercial strategy, and operational resilience to realize sustainable advantage. Leaders should prioritize modular platform designs and open instrument ecosystems that facilitate third-party consumable integration and reduce total cost of ownership for customers. Investing in reagent reliability and standardized library preparation kits, coupled with clear validation protocols, will decrease onboarding friction for clinical and high-throughput research users. Simultaneously, embedding robust analytics capabilities-covering alignment, assembly, annotation, and variant calling-into product suites or service offerings will enhance the perceived value proposition and enable customers to derive actionable insights more rapidly.

On the procurement and supply side, firms must diversify sourcing and consider regional manufacturing partnerships to mitigate trade and tariff risks. Building service-centric revenue streams through contract sequencing, tailored panel design, and managed data interpretation services can smooth revenue volatility and foster deeper client relationships. Regulatory engagement is also critical: proactively supporting customers with validation packages, compliance documentation, and post-market surveillance evidence will accelerate clinical adoption and reduce barriers to reimbursement. Finally, workforce strategies that combine training programs, embedded technical support, and collaborative research initiatives will help organizations maintain high service standards and scale operations without compromising quality.

Transparent multi-source research methodology combining stakeholder interviews literature synthesis and workflow analysis to validate industry insights and conclusions

The research methodology underpinning this executive summary integrates multiple qualitative and quantitative approaches to ensure robust, reproducible findings. Primary research included structured interviews with industry executives, laboratory directors, and procurement specialists to capture firsthand perspectives on technology adoption, validation requirements, and supply chain dynamics. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, technical white papers, and company disclosures to validate trends and contextualize interview insights within the broader scientific and commercial environment. Triangulation across these sources was applied to minimize bias and to corroborate thematic conclusions.

Analytical frameworks focused on value-chain decomposition, workflow mapping, and capability gap analysis to identify where friction and opportunity coexist. Segmentation analyses were constructed to reflect real-world purchasing and operational behaviors, aligning offerings, workflows, technology types, applications, and end users to practical considerations for deployment and scale. Quality control measures included cross-validation of technical claims with independent laboratory reports and confirmation of supply chain assertions through multiple distributor interviews. The methodology privileges transparency in assumptions, replicable search strategies for literature synthesis, and clear documentation of interview protocols to support future updates and bespoke research extensions.

Concise synthesis of implications from technological regulatory and commercial trends that define priorities for resilient capability building and competitive positioning

The conclusion synthesizes the core implications of technological advancement, regulatory evolution, regional divergence, and commercial strategy for stakeholders operating in the sequencing domain. Technological improvements in chemistry and platform design are expanding the range of feasible applications, while services and consumable specialization provide flexible pathways for adoption without extensive capital investment. Regulatory and trade shifts underscore the need for operational adaptability, particularly in procurement and supply chain planning, and for proactive engagement with certification and reimbursement stakeholders. Collectively, these dynamics favor organizations that can combine reliable instrumentation, validated consumables, integrated analytics, and responsive support networks.

Going forward, success will hinge on balancing immediate operational imperatives-such as securing resilient supply chains and ensuring analytical reproducibility-with sustained investments in platform differentiation and workforce capabilities. Organizations that pursue strategic partnerships, localize critical supply functions where appropriate, and deliver clear validation packages will lower barriers to adoption in clinical and research settings. Equally important are investments in secure, scalable data infrastructure and advanced bioinformatics to convert raw sequencing outputs into clinically meaningful and scientifically rigorous insights. This integrated approach positions stakeholders to capitalize on evolving opportunities while managing the complexities inherent in a fast-moving technological and regulatory environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of real-time nanopore sequencing for portable field diagnostics and epidemiology
  • 5.2. Advancements in single-cell multi-omics integration enabling high-resolution cellular profiling
  • 5.3. Clinical adoption of liquid biopsy assays leveraging ctDNA for early cancer detection and monitoring
  • 5.4. Development of long-read sequencing platforms improving structural variant detection in complex genomes
  • 5.5. Expansion of CRISPR-based sequencing methods for targeted enrichment and methylation analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Sequencing Market, by Offerings

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Buffers
    • 8.1.2. Primers & Probes
  • 8.2. Instruments & Platforms
    • 8.2.1. DNA Sequencers
    • 8.2.2. Library Preparation Systems
    • 8.2.3. PCR Machines
  • 8.3. Services
    • 8.3.1. Contract Sequencing
    • 8.3.2. Custom Panel Design
    • 8.3.3. Data Analysis & Interpretation

9. DNA Sequencing Market, by Workflow

  • 9.1. Data Analysis
    • 9.1.1. Alignment & Assembly
    • 9.1.2. Annotation
    • 9.1.3. Variant Calling
  • 9.2. Library Preparation
  • 9.3. Sample Preparation
    • 9.3.1. DNA Extraction
    • 9.3.2. Quality Control
  • 9.4. Sequencing

10. DNA Sequencing Market, by Technology Type

  • 10.1. Next-Generation Sequencing (NGS)
  • 10.2. Sanger Sequencing
  • 10.3. Third-Generation Sequencing (TGS)

11. DNA Sequencing Market, by Application

  • 11.1. Agricultural Genomics
  • 11.2. Drug Discovery
  • 11.3. Genetic Disease Research
  • 11.4. Microbiology
    • 11.4.1. Microbiome Analysis
    • 11.4.2. Pathogen Detection
  • 11.5. Oncology
    • 11.5.1. Cancer Genotyping
    • 11.5.2. Tumor Profiling
  • 11.6. Personalized Medicine
  • 11.7. Prenatal Testing

12. DNA Sequencing Market, by End User

  • 12.1. Academic & Research Institutions
    • 12.1.1. Government Research Institutes
    • 12.1.2. University Labs
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Diagnostic Laboratories
  • 12.4. Pharmaceutical & Biotechnology Companies

13. DNA Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Agilent Technologies, Inc.
    • 16.3.2. Becton, Dickinson and Company
    • 16.3.3. BGI Genomics Co., Ltd.
    • 16.3.4. Bio-Rad Laboratories, Inc.
    • 16.3.5. Eurofins Scientific SE
    • 16.3.6. F. Hoffmann-La Roche Ltd.
    • 16.3.7. Laboratory Corporation of America Holdings
    • 16.3.8. Azenta, Inc.
    • 16.3.9. Illumina, Inc.
    • 16.3.10. Macrogen Inc.
    • 16.3.11. Oxford Nanopore Technologies PLC
    • 16.3.12. PerkinElmer, Inc.
    • 16.3.13. QIAGEN N.V.
    • 16.3.14. Myriad Genetics, Inc.
    • 16.3.15. Thermo Fisher Scientific Inc.
    • 16.3.16. Twist Bioscience Corporation
    • 16.3.17. Abbott Laboratories
    • 16.3.18. Danaher Corporation
    • 16.3.19. Merck KGaA
    • 16.3.20. Pacific Biosciences of California, Inc.
    • 16.3.21. Novogene Co, Ltd.
    • 16.3.22. Shimadzu Corporation
    • 16.3.23. Genomics England
    • 16.3.24. Eppendorf SE
    • 16.3.25. 10x Genomics, Inc.
    • 16.3.26. BioChain Institute Inc.
    • 16.3.27. Genscript Biotech Corporation
    • 16.3.28. Sartorius AG
    • 16.3.29. Charles River Laboratories International, Inc.
    • 16.3.30. Johnson & Johnson Services, Inc.
    • 16.3.31. AbbVie Inc.
    • 16.3.32. Partek Inc.
    • 16.3.33. Novartis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DNA SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DNA SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DNA SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DNA SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DNA SEQUENCING MARKET SIZE, BY CUSTOM PANEL DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DNA SEQUENCING MARKET SIZE, BY ALIGNMENT & ASSEMBLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DNA SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DNA SEQUENCING MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRICULTURAL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIOME ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DNA SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DNA SEQUENCING MARKET SIZE, BY CANCER GENOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DNA SEQUENCING MARKET SIZE, BY TUMOR PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DNA SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS DNA SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS DNA SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. NO